Dyslipidemia is an independent risk factor for cardiovascular events. Statins have become the cornerstone for the prevention and treatment of atherosclerotic vascular diseases. However, after the comprehensive control of the traditional risk factors, including unhealthy lifestyle, hypercholesterolemia, hypertension, hyperglycemia and obesity, there is still a high risk of residual cardiovascular disease in patients with dyslipidemia. Triglyceride elevation is the most common type of dyslipidemia and constitutes an important component of cardiovascular residual risk.
The geraniol has a variety of pharmacological effects, such as anti-inflammatory, antioxidant, regulating cell apoptosis. Recent studies have confirmed that geraniol plays an important role in regulating glucose and lipid metabolism, and may have a synergistic role with statins. Gefarnate Tablets is a kind of anti-ulcer and gastritis treatment. It can increase the defense ability of gastric mucosa by improving the prostaglandin level and the concentration of amino hexose in the gastric mucosa. Geraniol is the main components of Gefarnate Tablets. In the previous study, the investigators found that geraniol induced autophagy through the SIRT1-AMPK-mTOR pathway and accelerated the degradation of triglycerides in liver cells, thus reducing the level of triglyceride in the serum of high fat diet mice. 6 patients with hyperlipidemia were received Gefarnate Tablets (100mg/ times, 3 times per day). A month later, the levels of serum triglyceride, total cholesterol, and low density lipoprotein cholesterol were decreased significantly. However, the above results need to be confirmed by the larger clinical research.
Therefore, the aim of this study is to evaluate the effect of Gefarnate Tablets on blood lipid levels in patients with hypertriglyceridemia and coronary heart disease treated with statins, provide more options for the treatment of lipid lowering treatment, reduce the risk of cardiovascular remnant, and improve the long-term prognosis of the coronary heart disease patients with residual hypertriglyceridemia.

开始日期2019-09-01

申办/合作机构

哈尔滨医科大学附属第一医院

NCT01051388 / Completed临床3期IIT

Prophylactic Efficacy of Proton Pump Inhibitor on Recurrence of Peptic Ulcer in Patients Continuously Treated With Low-dose Aspirin-Randomized, Multi-center, Single-blinded, Parallel-group, Comparative Study

The aim of this study is to evaluate the efficacy of proton pump inhibitor (PPI), comparing to the mucosal defensive drug, in the prevention of the recurrence of gastric and/or duodenal ulcers during 12 weeks observation in patients receiving low-dose aspirin for vascular protection.

开始日期2008-08-01

申办/合作机构-

100 项与吉法酯相关的临床结果

登录后查看更多信息

100 项与吉法酯相关的转化医学

登录后查看更多信息

100 项与吉法酯相关的专利（医药）

登录后查看更多信息

160

项与吉法酯相关的文献（医药）

2024-12-01·Neurochemical Research

Neuroprotective Properties of Coriander-Derived Compounds on Neuronal Cell Damage under Oxidative Stress-Induced SH-SY5Y Neuroblastoma and in Silico ADMET Analysis

Article

作者: Intharakham, Saruta ; Prachayasittikul, Virapong ; Prachayasittikul, Veda ; Jongwachirachai, Papitcha ; Prachayasittikul, Supaluk ; Apiraksattayakul, Setthawut ; Suwanjang, Wilasinee ; Ruankham, Waralee ; Phopin, Kamonrat

AbstractAn imbalance between reactive oxygen species (ROS) production and antioxidant defense driven by oxidative stress and inflammation is a critical factor in the progression of neurodegenerative diseases such as Alzheimer’s and Parkinson’s. Coriander (Coriandrum sativum L.), a culinary plant in the Apiaceae family, displays various biological activities, including anticancer, antimicrobial, and antioxidant effects. Herein, neuroprotective properties of three major bioactive compounds derived from coriander (i.e., linalool, linalyl acetate, and geranyl acetate) were investigated on hydrogen peroxide-induced SH-SY5Y neuroblastoma cell death by examining cell viability, ROS production, mitochondrial membrane potential, and apoptotic profiles. Moreover, underlying mechanisms of the compounds were determined by measuring intracellular sirtuin 1 (SIRT1) enzyme activity incorporated with molecular docking. The results showed that linalool, linalyl acetate, and geranyl acetate elicited their neuroprotection against oxidative stress via protecting cell death, reducing ROS production, preventing cell apoptosis, and modulating SIRT1 longevity. Additionally, in silico pharmacokinetic predictions indicated that these three compounds are drug-like agents with a high probability of absorption and distribution, as well as minimal potential toxicities. These findings highlighted the potential neuroprotective linalool, linalyl acetate, and geranyl acetate for developing alternative natural compound-based neurodegenerative therapeutics and prevention.

2024-10-01·Food and Chemical Toxicology

RIFM fragrance ingredient safety assessment, geranyl acetate, CAS registry number 105-87-3

Review

作者: Penning, T. M. ; Siddiqi, F. ; Lapczynski, A. ; Chon, H. ; Sipes, I. G. ; Bruze, M. ; Moustakas, H. ; Kumar, M. ; Fryer, A. D. ; Romine, J. ; Deodhar, C. ; Ritacco, G. ; Api, A. M. ; Date, M. ; Sadekar, N. ; Botelho, D. ; Lavelle, M. ; Belsito, D. ; Schultz, T. W. ; Thakkar, Y. ; Burton, G. A. Jr. ; Sullivan, G. ; Joshi, K. ; Cancellieri, M. A. ; Lee, I. ; Tokura, Y. ; Dekant, W. ; Liebler, D. C. ; Selechnik, D. ; Dagli, M. L. ; Jones, L. ; Na, M.

A review.The existing information supports the use of this material as described in this safety assessment.Geranyl formate was evaluated for genotoxicity, repeated dose toxicity, reproductive toxicity, local respiratory toxicity, photoirritation/photoallergenicity, skin sensitization, and environmental safety.Data show that geranyl formate is not genotoxic.Data from read-across analog geranyl acetate (CAS # 105-87-3) provide a Margin of Exposure (MOE) > 100 for the repeated dose toxicity endpoint and a No Expected Sensitization Induction Level (NESIL) of 5000μg/cm2 for the skin sensitization endpoint.Data from analog neryl acetate (CAS # 141-12-8) provide an MOE >100 for the reproductive toxicity endpoint.The photoirritation/ photoallergenicity endpoints were evaluated based on UV/visible (UV/Vis) spectra; geranyl formate is not expected to be photoirritating/photoallergenic.The local respiratory toxicity endpoint was evaluated using the Threshold of Toxicol. Concern (TTC) for a Cramer Class I material; exposure to geranyl formate is below the TTC (1.4 mg/day).The environmental endpoints were evaluated; geranyl formate was found not to be Persistent, Bioaccumulative, and Toxic (PBT) as per the International Fragrance Association (IFRA) Environmental Standards, and its risk quotients, based on its current volume of use in Europe and North America (i.e., Predicted Environmental Concentration/Predicted No Effect Concentration [PEC/PNEC]), are <1.

2024-10-01·Food and Chemical Toxicology

RIFM fragrance ingredient safety assessment, geranyl linalool, CAS registry number 1113-21-9

Review

作者: Penning, T. M. ; Siddiqi, F. ; Lapczynski, A. ; Sipes, I. G. ; Chon, H. ; Bruze, M. ; Moustakas, H. ; Kumar, M. ; Fryer, A. D. ; Romine, J. ; Deodhar, C. ; Ritacco, G. ; Api, A. M. ; Date, M. ; Sadekar, N. ; Botelho, D. ; Lavelle, M. ; Belsito, D. ; Schultz, T. W. ; Thakkar, Y. ; Burton, G. A. Jr. ; Joshi, K. ; Sullivan, G. ; Cancellieri, M. A. ; Lee, I. ; Tokura, Y. ; Dekant, W. ; Liebler, D. C. ; Dagli, M. L. ; Selechnik, D. ; Jones, L. ; Na, M.

A review.Geranyl butyrate was evaluated for genotoxicity, repeated dose toxicity, reproductive toxicity, local respiratory toxicity, photoirritation/photoallergenicity, skin sensitization, and environmental safety.Data from read-across analog geranyl acetate (CAS # 105-87-3) show that geranyl butyrate is not expected to be genotoxic and provide a calculated Margin of Exposure (MOE) > 100 for the repeated dose toxicity endpoint and a No Expected Sensitization Induction Level (NESIL) of 5000μg/cm² for the skin sensitization endpoint.Data on read-across analog neryl acetate (CAS # 141-12-8) provide an MOE >100 for the reproductive toxicity endpoint.The photoirritation/photoallergenicity endpoints were evaluated based on UV spectra; geranyl butyrate is not expected to be photoirritating/ photoallergenic.The local respiratory toxicity endpoint was evaluated using the Threshold of Toxicol. Concern (TTC) for a Cramer Class I material; exposure is below the TTC (1.4 mg/day).The environmental endpoints were evaluated; geranyl butyrate was found not to be Persistent, Bioaccumulative, and Toxic (PBT) as per the International Fragrance Association (IFRA) Environmental Standards, and its risk quotients, based on its current volume of use (VoU) in Europe and North America (i. e., Predicted Environmental Concentration/Predicted No Effect Concentration [PEC/PNEC]), are <1.

100 项与吉法酯相关的药物交易

登录后查看更多信息